The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review

Yuanyuan Ma, Zhi‐Yuan Zhou, Guo‐Yuan Yang, Jing Ding, Xin WangFrontiers in Pharmacology 2022 · DOI

This review paper, published in Frontiers in Pharmacology, provides a comprehensive synthesis of the therapeutic potential of Erythropoietin (EPO) and its engineered derivatives for treating ischemic stroke. It bridges the gap between EPO’s established role in hematology and its emerging, complex role as a neuroprotective agent in the central nervous system (CNS).

TL;DR

This review evaluates Erythropoietin (EPO) as a multi-modal therapy for ischemic stroke, highlighting its ability to trigger neuroprotection, angiogenesis, and anti-inflammatory pathways. While standard recombinant human EPO (rhEPO) faces challenges like increased thrombosis risk, the paper identifies non-hematopoietic EPO derivatives (like CEPO and Neuro-EPO) as promising candidates that offer brain-saving benefits without the dangerous side effects of increased red blood cell production.

What Problem Does This Paper Address?

Ischemic stroke remains a leading cause of global mortality and disability, yet therapeutic options are largely limited to rapid thrombolysis (clot-busting). While EPO—a hormone primarily known for regulating red blood cell production—has shown remarkable neuroprotective qualities in the lab, its clinical translation has been rocky.

The primary challenges addressed are:

  1. Side Effects: High doses of rhEPO required for neuroprotection can increase blood viscosity and the risk of secondary strokes or thrombosis.
  2. Blood-Brain Barrier (BBB): Systemic EPO has poor penetration into the brain.
  3. Clinical Inconsistency: Early human trials were promising, but larger trials (like the German Multicenter EPO Stroke Trial) showed increased mortality when EPO was combined with standard treatments like rtPA.

Methods

As a comprehensive review, the authors synthesized data from three decades of research, including:

  • Molecular Biology: Analysis of EPO receptor (EPOR) signaling pathways (e.g., JAK2/STAT, PI3K/AKT, and MAPK).
  • Pre-clinical Models: Evaluation of rhEPO in Middle Cerebral Artery Occlusion (MCAO) rodent models.
  • Clinical Trial Meta-analysis: Reviewing outcomes from major human trials (Phase II/III) to identify why results varied.
  • Pharmacological Engineering: Comparing the structural modifications of EPO derivatives designed to decouple "blood-building" from "brain-protecting" functions.

Datasets

The paper does not introduce a new dataset but serves as a meta-analytical hub for:

  • Clinical Trial Data: Including the 2002 Ehrenreich study (positive), the 2009 German Multicenter trial (negative/safety concerns), and the PENUT trial for neonatal neuroprotection.
  • Structural Biology: Utilizing Protein Data Bank (PDB) structures (e.g., PBD ID: EER) to explain the glycosylation patterns of EPO.

Key Insights and Ideas

  • The Dual-Receptor Hypothesis: EPO appears to interact with two distinct receptor types. The classical homodimeric receptor (EPOR/EPOR) triggers erythropoiesis (blood production). However, a heterodimeric receptor (EPOR/βcR) is believed to mediate tissue repair and anti-apoptotic effects. Targeting the latter specifically is the "holy grail" of EPO therapy.
  • Intranasal Delivery as a Game Changer: The review highlights that intranasal administration bypasses the BBB and the liver's first-pass effect, allowing for higher CNS concentrations with lower systemic exposure, potentially mitigating thrombosis risks.
  • The "rtPA Interaction" Warning: A critical insight is the potential danger of combining rhEPO with rtPA (recombinant tissue plasminogen activator). Clinical data suggests this combination might exacerbate brain hemorrhage, a finding that halted several clinical applications.
  • Neuro-EPO and CEPO: These derivatives are "non-hematopoietic." For example, Carbamylated EPO (CEPO) does not bind to the classical erythropoietic receptor but still activates neuroprotective pathways, effectively separating the drug's benefits from its primary side effect.

Key Results

  • Pre-clinical Success: In animal models, rhEPO consistently reduces infarct volume and improves neurological scores by suppressing inflammation and oxidative stress.
  • Mixed Human Outcomes: While a 2013 trial showed high-dose EPO in the first 24 hours was effective in reducing complications, the 2009 Phase II/III trial (n=460) showed no improvement in Barthel Index scores and a higher overall death rate in the EPO group.
  • Derivative Efficacy: Neuro-EPO showed a 25% higher viability efficacy than standard controls in Mongolian gerbil models of ischemia, with no observed increase in hematocrit (red blood cell count).

Limitations and Future Work

  • The Translation Gap: The authors acknowledge a significant "failure to translate" from successful rodent studies to human patients. They suggest this is due to differences in timing, dosage, and the presence of comorbidities (age, hypertension) in humans that are often absent in lab animals.
  • Need for Isoform Specificity: Future research must focus on developing ligands that are highly selective for the EPOR/βcR tissue-repair receptor.
  • Refining Combination Therapies: More work is needed to understand the molecular crosstalk between EPO and thrombolytic agents to ensure they can be used together safely.
  • Long-term Chronic Studies: Most research focuses on the acute phase; the review calls for more studies on EPO's role in long-term recovery and cognitive rehabilitation post-stroke.

Summary updated

Abstract

Numerous studies explored the therapeutic effects of erythropoietin (EPO) on neurodegenerative diseases. Few studies provided comprehensive and latest knowledge of EPO treatment for ischemic stroke. In the present review, we introduced the structure, expression, function of EPO, and its receptors in the central nervous system. Furthermore, we comprehensively discussed EPO treatment in pre-clinical studies, clinical trials, and its therapeutic mechanisms including suppressing inflammation. Finally, advanced studies of the therapy of EPO derivatives in ischemic stroke were also discussed. We wish to provide valuable information on EPO and EPO derivatives' treatment for ischemic stroke for basic researchers and clinicians to accelerate the process of their clinical applications.
BibTeX
@inproceedings{ma2022effect,
  author = {Yuanyuan Ma and Zhi‐Yuan Zhou and Guo‐Yuan Yang and Jing Ding and Xin Wang},
  title = {{The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.743926},
}
Figure